New Breath Testing Data Using Gemelli Biotech’s Trio-Smart to Be Presented at DDW 2024
May 16 2024 - 11:43AM
Business Wire
Gemelli Biotech and its technologies (Trio-Smart® and
IBS-Smart®) will be featured in numerous presentations at DDW
2024.
Three-Gas Breath Testing Technology
Many of these findings were determined using the proprietary
breath testing instruments and state-of-the-art collection kits
developed and distributed by Gemelli Biotech using the only
three-gas, mail-in breath test on the market, Trio-Smart®. This
test measures the three primary fermented gases in the gut
microbiome: hydrogen, methane, and hydrogen sulfide. Trio-Smart is
an at-home, mail-in breath test that is a Laboratory Developed Test
(LDT) conducted at a CLIA-certified lab.
“Gemelli continues to build on our previous work, measuring
methane, hydrogen, and hydrogen sulfide. In fact, the Trio-Smart
breath test is the most validated breath test to date based on
recent publications and new data being presented at DDW. A recent
study (Villanueva, et al. Am J Gastroenterol 2022) was the first
study ever to compare diarrhea and constipation symptoms of
irritable bowel syndrome (IBS) and the actual microbiome to the
results of the Trio-Smart breath test. This study confirmed that
the levels of methane and hydrogen sulfide on our test do, in fact,
predict the actual microbiome composition. This is a first,” said
Matt Mitcho, CEO of Gemelli Biotech.
“This DDW takes the validation to its completion. Studies will
be presented that show that the Trio-Smart system is the only
system validly correlating methane on breath with methane producers
in the small intestine using next-generation shotgun sequencing,
and the only breath test measuring hydrogen sulfide which also
correlates with hydrogen sulfide-producing small bowel bacteria.
This finding supports the levels of gases on breath as valid and
representative of the microbiome. No breath test has ever gone
through this rigorous affirmation,” Mitcho declares. “This is a
major milestone for patients suffering from chronic intestinal
illnesses and a testament to the integrity and leading position of
this breath test technology in the market to achieve these major
milestones. When it comes to comparing the breath test to symptoms
in the human gut microbiome (and, in particular, the small
intestinal microbiome), this is the most accurate and validated
breath test on the market, as no other technology has completed
these comprehensive microbiome studies in breath test
patients.”
Finally, the entire Gemelli testing platform was put to the test
in a large-scale, real-world study comparing the testing results
nationwide and comparing the results to symptoms. “We are excited
by all the new developments and look forward to sharing more
details during the meeting,” exclaims Mitcho.
Learn more about Trio-Smart - www.triosmartbreath.com.
The following abstracts will be presented at DDW held in
Washington, D.C. on May 18–21, 2024:
- Mail-in breath testing reveals the relationship between
exhaled methane and gastrointestinal symptoms: a large-scale
nationwide study of community practices (5/19/24 12:30-1:30pm
POSTER #Su1659)
- Multiple methane producers in the small intestine by shotgun
sequencing correlate with methane levels on breath testing
(5/19/24 12:30-1:30pm POSTER #Su1895)
- Hydrogen sulfide producers in the duodenum by shotgun
sequencing correlate with hydrogen sulfide levels on breath
testing (5/20/24 10:30am Session #4270, ROOM 103AB)
- Changes in anti-vinculin antibodies over time correlate with
symptom improvement in irritable bowel syndrome (IBS) (5/21/24
12:30-1:30pm POSTER #Tu1650)
About Gemelli Biotech
Gemelli Biotech develops and distributes at-home, mail-in
precision diagnostics for diseases of the gut microbiome. Our
mission is to leverage leading biological discoveries related to
the microbiome to provide non-invasive, easy-to-understand
diagnostics. This enables clinicians to definitively detect
scientifically validated biomarkers and optimally treat GI diseases
including IBS, SIBO, IMO, and ISO. Our products include the
Trio-Smart® breath test that measures levels of hydrogen, methane,
and hydrogen sulfide; the IBS-Smart® blood test that measures
validated biomarkers of IBS, anti-CdtB, and anti-vinculin, offering
a positive diagnostic strategy for patients with IBS symptoms; and
the Trio-Smart Malabsorption test that helps identify carbohydrate
intolerances after lactose, fructose, or sucrose consumption.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515599783/en/
Investor Relations - hello@gemellibiotech.com